Report on the Global AIDS Epidemic 2008. UNAIDS web site. Available at: www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp
. Last accessed February 11, 2010.
Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.CrossRefPubMed
Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–29.CrossRefPubMed
Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563–608.CrossRefPubMed
Hammer SM, Eron JJ Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–570.CrossRefPubMed
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; December 1, 2009:1–161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Last accessed: February 11, 2010.
Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. World Health Organization ART Guideline Review Committee; November 2009. Available at: www.who.int/hiv/pub/arv/rapid_advice_art.pdf
. Last accessed: February 11, 2010.
Epzicom (package insert). Research Triangle Park, NC: GlaxoSmithKline; 2009.
Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci. 2009;46:153–165.CrossRefPubMed
Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–1426.CrossRefPubMed
Lundgren JD, Neuhaus J, Babiker A, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–F24.CrossRef
Lang SM-KM, Cotte L, Gilquin L, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS C04. Abstract presented at: 16th Conference on Retroviruses and Oppotunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract #43LB.
Obel N, Farkas D, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11:130–136.CrossRefPubMed
Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230–2240.CrossRefPubMed
Baker KL, Lou Y, Yuen G, Murray S, Stein D. The bioequivalence and effect of food on a new once-a-day fixed-dose combination tablet of abacavir (ABC) and lamivudine (3TC). Poster presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 30, 2004–November 2, 2004; Washington, DC.
Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 1999;19:932–942.CrossRefPubMed
Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47:351–371.CrossRefPubMed
Ziagen (package insert). Research Park Triangle, NC: GlaxoSmithKline; 2009.
Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006;20:553–560.CrossRefPubMed
Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron. 2001;89:62–67.CrossRefPubMed
Foster RH, Faulds D. Abacavir. Drugs. 1998;55:729–736; discussion 737-738.CrossRefPubMed
Moyle G, Boffito M, Fletcher C, et al. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2009;53:1532–1538.CrossRefPubMed
Hawkins T, Veikley W, St. Claire RL 3rd, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39:406–411.CrossRefPubMed
Harris M, Back D, Kewn S, Jutha S, Marina R, Montaner JS. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS. 2002;16:1196–1197.CrossRefPubMed
Piliero P, Shachoy-Clark AD, Para M, et al. A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK Protocol CNA 10905). Abstract presented at: 43rd International Conference on Antimicrobial Agents and Chemotherapy. September 14–17, 2003; Chicago, IL, USA. Abstract A-1797.
Weller S, Radomski KM, Lou Y, Stein DS. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2000;44:2052–2060.CrossRefPubMed
Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviralnaive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417–425.CrossRefPubMed
Goicoechea M, Jain S, Kemper C, et al., editors. Viral Dynamics and Pharmacokinetics in vivo of Tenofovir Disoproxil Fumarate and Abacavir: Evidence of a Non-additive Antiviral Effect. Poster presented at: 16th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montréal, Canada. Poster no. 703.Available at: www.hivandhepatitis.com/2009icr/croi/pdf/3Golcoechea.pdf
McDowell JA, Lou Y, Symonds WS, Stein DS. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44:2061–2067.CrossRefPubMed
Mastroianni CM, d’Ettorre G, Vullo V. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. Expert Opin Pharmacother. 2006;7:2233–2241.CrossRefPubMed
DiCenzo R, Forrest A, Squires KE, et al. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003;47:1929–1935.CrossRefPubMed
Waters L, Moyle G, D’Avolio A, et al., editors. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther. 2007;12:825–380.PubMed
Aptivus (package insert). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2009.
McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44:1686–1690.CrossRefPubMed
Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr. 2007;45:123–125.PubMed
Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol. 1995;35:1174–1180.PubMed
Epivir (package insert). Research Triangle Park, NC: GlaxoSmithKline; 2009.
Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41–66.CrossRefPubMed
Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178:1327–1333.CrossRefPubMed
Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40:1514–1519.PubMed
Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol. 1998;54:363–366.CrossRefPubMed
Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther. 1996;59:550–558.CrossRefPubMed
Moore KH, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999;13:2239–2250.CrossRefPubMed
Bruno R, Regazzi MB, Ciappina V, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet. 2001;40:695–700.CrossRefPubMed
Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48:176–182.CrossRefPubMed
DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39:411–418.CrossRefPubMed
Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53:1937–1943.CrossRefPubMed
Yuen GJ, Lou Y, Thompson NF, et al.et al. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol. 2001;41:277–288.CrossRefPubMed
Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother. 2005;49:3997–4008.CrossRefPubMed
Cohen CJ, Kubota M, Brachman PS, et al. Shortterm safety and tolerability of a once-daily fixeddose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study. Pharmacotherapy. 2008;28:314–322.CrossRefPubMed
Goedken AM, Herman RA. Once-daily abacavir in place of twice-daily administration. Ann Pharmacother. 2005;39:1302–1308.CrossRefPubMed
Martinez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290–297.CrossRefPubMed
Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547–1556.CrossRefPubMed
Sosa N, Hill-Zabala C, Dejesus E, et al. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defic Syndr. 2005;40:422–427.CrossRefPubMed
Brothers CCA, Zhao H, Edwards M, Fleming J, Scott T. Once daily administration of abacavir is not a clinical risk factor for suspected hypersensitivity reactions in clinical trials and rash is not sufficient to diagnose the reaction. Poster presented at: 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA. February 23, 2005. Poster 836.
Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732.CrossRefPubMed
Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–1122.CrossRefPubMed
Mallal S, Phillips E, Carosi G, et al. HLAB* 5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.CrossRefPubMed
Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-hiv drugs (D:A:D) study. J Infect Dis. 2010;201:318–330.CrossRefPubMed
Calza L, Manfredi R, Colangeli V, et al. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS. 2009;23:691–697.CrossRefPubMed
Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7:85–98.CrossRefPubMed
Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007;44:540–550.CrossRefPubMed
Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20–28.CrossRefPubMed
Benson CRH, Zheng E, Koletar S, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. Abstract presented at: 16th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract #721.
Durand MSO, Baril JA. Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec’s public health insurance database (QPHID). Abstract presented at: 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 19–22, 2009; Cape Town, South Africa. Abstract #TUPEB175.
Bedimo RWA, Dreschler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. Abstract presented at: 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 19–22, 2009; Cape Town, South Africa. Abstract #MOAB202.
Post FA, Campbell LJ. Abacavir and increased risk of myocardial infarction. Lancet. 2008;372:803; author reply 4–5.CrossRef
Palella FGS, Elion R, Benning L, et al. Inflammatory markers among abacavir and non-abacavir recipients in the Womens’ Interagency HIV study and the Multicenter AIDS cohort study. Abstract presented at: 16th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract #150LB.
Martinez ELM, Perez I. No evidence for recent abacavir/lamivudine use in promoting inflammation, endothelial dysfunction, hypercoaguability, or insulin resistance in virologically suppressed HIV-infected patients: a substudy of the BICOMBO randomized clinical trial. 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 19–22, 2009; Cape Town, South Africa. Abstract #MOAB203.
Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS. 2009;23:2021–2027.CrossRefPubMed
Satchell C OCE, Peace A, Cotter A, Sheehan G, Tedesco T, Doran P, Powderly W, Kenny D, Mallon P. Platelet hyper-reactivity in HIV-1 infected patients on abacavir-containing ART. Abstract presented at: 15th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract #151LB.
DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39:1038–1046.CrossRefPubMed
Lamarca A, Clumeck N, Plettenberg A, et al. Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). J Acquir Immune Defic Syndr. 2006;41:598–606.CrossRefPubMed